FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:MAN2A1-UIMC1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: MAN2A1-UIMC1
FusionPDB ID: 51101
FusionGDB2.0 ID: 51101
HgeneTgene
Gene symbol

MAN2A1

UIMC1

Gene ID

4124

51720

Gene namemannosidase alpha class 2A member 1ubiquitin interaction motif containing 1
SynonymsAMan II|GOLIM7|MANA2|MANIIRAP80|X2HRIP110
Cytomap

5q21.3

5q35.2

Type of geneprotein-codingprotein-coding
Descriptionalpha-mannosidase 2Golgi alpha-mannosidase IIgolgi integral membrane protein 7mannosidase, alpha type IImannosyl-oligosaccharide 1,3-1,6-alpha-mannosidaseBRCA1-A complex subunit RAP80receptor-associated protein 80retinoid X receptor-interacting protein 110
Modification date2020031320200327
UniProtAcc

Q16706

Main function of 5'-partner protein: FUNCTION: Catalyzes the first committed step in the biosynthesis of complex N-glycans. It controls conversion of high mannose to complex N-glycans; the final hydrolytic step in the N-glycan maturation pathway. {ECO:0000250|UniProtKB:P28494}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000261483, ENST00000505313, 
ENST00000503273, ENST00000377219, 
ENST00000377227, ENST00000506128, 
ENST00000511320, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score14 X 12 X 8=13445 X 5 X 4=100
# samples 145
** MAII scorelog2(14/1344*10)=-3.26303440583379
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(5/100*10)=-1
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: MAN2A1 [Title/Abstract] AND UIMC1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: MAN2A1 [Title/Abstract] AND UIMC1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)MAN2A1(109178162)-UIMC1(176370489), # samples:1
Anticipated loss of major functional domain due to fusion event.MAN2A1-UIMC1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MAN2A1-UIMC1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MAN2A1-UIMC1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
MAN2A1-UIMC1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneUIMC1

GO:0045892

negative regulation of transcription, DNA-templated

12080054



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:109178162/chr5:176370489)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across MAN2A1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across UIMC1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000261483MAN2A1chr5109178162+ENST00000377227UIMC1chr5176370489-4746375273144681245
ENST00000261483MAN2A1chr5109178162+ENST00000377219UIMC1chr5176370489-4746375273144711246
ENST00000261483MAN2A1chr5109178162+ENST00000506128UIMC1chr5176370489-4701375273144681245
ENST00000261483MAN2A1chr5109178162+ENST00000511320UIMC1chr5176370489-4701375273144681245

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000261483ENST00000377227MAN2A1chr5109178162+UIMC1chr5176370489-0.0002615840.9997384
ENST00000261483ENST00000377219MAN2A1chr5109178162+UIMC1chr5176370489-0.0003009150.9996991
ENST00000261483ENST00000506128MAN2A1chr5109178162+UIMC1chr5176370489-0.0002869410.999713
ENST00000261483ENST00000511320MAN2A1chr5109178162+UIMC1chr5176370489-0.0002869410.999713

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MAN2A1-UIMC1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
MAN2A1chr5109178162UIMC1chr517637048937521006KSQNRFYTDLNGYQVGNKEDAEKEVA

Top

Potential FusionNeoAntigen Information of MAN2A1-UIMC1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
MAN2A1-UIMC1_109178162_176370489.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-A02:21YTDLNGYQV0.96050.639615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-A02:35YTDLNGYQV0.94590.5431615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-A02:38YTDLNGYQV0.93660.6422615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-A02:20YTDLNGYQV0.93420.5184615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C05:09YTDLNGYQV0.99990.955615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C04:10YTDLNGYQV0.99980.8926615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C08:15YTDLNGYQV0.99940.964615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C04:07YTDLNGYQV0.99930.8845615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C04:06YTDLNGYQV0.98830.9088615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C15:06YTDLNGYQV0.9780.8449615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C03:07YTDLNGYQV0.97330.9549615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-A02:07YTDLNGYQV0.95060.527615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C04:14YTDLNGYQV0.8910.9003615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C08:04YTDLNGYQV0.84310.9294615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C08:13YTDLNGYQV0.84310.9294615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C03:19YTDLNGYQV0.83760.9838615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C08:03YTDLNGYQV0.6260.9711615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C02:06YTDLNGYQV0.42450.9326615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C04:10FYTDLNGYQV0.99960.7051515
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C04:07FYTDLNGYQV0.99940.7042515
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C04:14FYTDLNGYQV0.90690.7321515
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C05:01YTDLNGYQV0.99990.955615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C04:03YTDLNGYQV0.99990.9103615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C18:01YTDLNGYQV0.99950.9017615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C08:02YTDLNGYQV0.99940.964615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C01:03YTDLNGYQV0.99930.8495615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C04:01YTDLNGYQV0.99930.8845615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C15:02YTDLNGYQV0.98820.8477615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C15:05YTDLNGYQV0.98330.8935615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C04:04YTDLNGYQV0.97270.865615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-A02:14YTDLNGYQV0.96080.5334615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-A02:06YTDLNGYQV0.96050.639615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-A68:02YTDLNGYQV0.9430.5711615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-A69:01YTDLNGYQV0.92930.6006615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C03:06YTDLNGYQV0.85540.9765615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C08:01YTDLNGYQV0.6260.9711615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C17:01YTDLNGYQV0.61150.8171615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C07:04YTDLNGYQV0.16820.9449615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-B07:13YTDLNGYQV0.01270.6975615
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C04:01FYTDLNGYQV0.99940.7042515
MAN2A1-UIMC1chr5109178162chr51763704893752HLA-C18:01FYTDLNGYQV0.9990.752515

Top

Potential FusionNeoAntigen Information of MAN2A1-UIMC1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
MAN2A1-UIMC1_109178162_176370489.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0101NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0101QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0101RFYTDLNGYQVGNKE419
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0103NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0105NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0105QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0105RFYTDLNGYQVGNKE419
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0107NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0107QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0107RFYTDLNGYQVGNKE419
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0109NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0109QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0109RFYTDLNGYQVGNKE419
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0111NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0111QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0113NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0113QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0115NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0115QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0115RFYTDLNGYQVGNKE419
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0117NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0117QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0119NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0119QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0119RFYTDLNGYQVGNKE419
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0121NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0121QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0125NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0125QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0125RFYTDLNGYQVGNKE419
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0127NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0127QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0127RFYTDLNGYQVGNKE419
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0129NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0129QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0131NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0131QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0131RFYTDLNGYQVGNKE419
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0401QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0401SQNRFYTDLNGYQVG116
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0433QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0433SQNRFYTDLNGYQVG116
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0434QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0434SQNRFYTDLNGYQVG116
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0435QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0435SQNRFYTDLNGYQVG116
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0438QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0438SQNRFYTDLNGYQVG116
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0462QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0463QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0463SQNRFYTDLNGYQVG116
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0464QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0466QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0466SQNRFYTDLNGYQVG116
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0472QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0472SQNRFYTDLNGYQVG116
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0476QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-0476SQNRFYTDLNGYQVG116
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1216NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1515NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1527NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1527QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1534NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1534QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1601NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1601QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1602NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1602QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1603NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1603QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1604NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1604QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1605NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1605QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1607NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1607QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1608NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1608QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1609NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1609QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1610NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1610QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1611NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1611QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1612NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1612QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1614NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1614QNRFYTDLNGYQVGN217
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1616NRFYTDLNGYQVGNK318
MAN2A1-UIMC1chr5109178162chr51763704893752DRB1-1616QNRFYTDLNGYQVGN217

Top

Fusion breakpoint peptide structures of MAN2A1-UIMC1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10827YTDLNGYQVGNKEDMAN2A1UIMC1chr5109178162chr51763704893752

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MAN2A1-UIMC1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN10827YTDLNGYQVGNKED-7.9962-8.1096
HLA-B14:023BVN10827YTDLNGYQVGNKED-5.70842-6.74372
HLA-B52:013W3910827YTDLNGYQVGNKED-6.83737-6.95077
HLA-B52:013W3910827YTDLNGYQVGNKED-4.4836-5.5189
HLA-A11:014UQ210827YTDLNGYQVGNKED-10.0067-10.1201
HLA-A11:014UQ210827YTDLNGYQVGNKED-9.03915-10.0745
HLA-A24:025HGA10827YTDLNGYQVGNKED-6.56204-6.67544
HLA-A24:025HGA10827YTDLNGYQVGNKED-5.42271-6.45801
HLA-B44:053DX810827YTDLNGYQVGNKED-7.85648-8.89178
HLA-B44:053DX810827YTDLNGYQVGNKED-5.3978-5.5112
HLA-A02:016TDR10827YTDLNGYQVGNKED-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of MAN2A1-UIMC1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
MAN2A1-UIMC1chr5109178162chr5176370489515FYTDLNGYQVTATACTGACCTAAATGGGTACCAGGTTGGT
MAN2A1-UIMC1chr5109178162chr5176370489615YTDLNGYQVACTGACCTAAATGGGTACCAGGTTGGT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
MAN2A1-UIMC1chr5109178162chr5176370489116SQNRFYTDLNGYQVGCAAAATAGATTTTATACTGACCTAAATGGGTACCAGGTTGGTAAC
MAN2A1-UIMC1chr5109178162chr5176370489217QNRFYTDLNGYQVGNAATAGATTTTATACTGACCTAAATGGGTACCAGGTTGGTAACAAG
MAN2A1-UIMC1chr5109178162chr5176370489318NRFYTDLNGYQVGNKAGATTTTATACTGACCTAAATGGGTACCAGGTTGGTAACAAGGAA
MAN2A1-UIMC1chr5109178162chr5176370489419RFYTDLNGYQVGNKETTTTATACTGACCTAAATGGGTACCAGGTTGGTAACAAGGAAGAT

Top

Information of the samples that have these potential fusion neoantigens of MAN2A1-UIMC1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
Non-CancerMAN2A1-UIMC1chr5109178162ENST00000261483chr5176370489ENST00000377219ERR315417

Top

Potential target of CAR-T therapy development for MAN2A1-UIMC1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneMAN2A1chr5:109178162chr5:176370489ENST00000261483+17226_269001145.0TransmembraneHelical%3B Signal-anchor for type II membrane protein

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to MAN2A1-UIMC1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to MAN2A1-UIMC1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource